Léa Liaigre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Léa Liaigre has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Matthieu Roustit
Univ. Grenoble Alpes, Inserm CIC1406, CHU Grenoble Alpes
3 shared publications Arnaud Tanty
Centre hospitalier universitaire Grenoble Alpes, avenue Maquis-du-Grésivaudan, 38700 La Tronche, France
2 shared publicationsBruno Degano
Thorax and Vascular Department, Pneumology Clinic, Univ. Grenoble Alpes, Grenoble Alpes University Hospital
2 shared publicationsClaire Trochet
Centre hospitalier universitaire Grenoble Alpes, avenue Maquis-du-Grésivaudan, 38700 La Tronche, France
2 shared publicationsPierrick Bedouch
Pharmacy Department, Grenoble Alpes University Hospital
2 shared publications- Pierrick Bedouch
CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, Université Grenoble Alpes, Grenoble, France
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Digital Health
- Vol. 8, 1834577
Assessing knowledge and perception of artificial intelligence in solid organ transplantation
Introduction: Artificial intelligence (AI) is increasingly integrated into healthcare, reshaping clinical decision-making and care pathways. In solid organ transplantation (SOT), where clinical complexity and uncertainty are high, AI holds particular promise. Yet, beyond technical performance, its successful adoption depends on how it is understood and perceived by patients and healthcare professionals (HP). To date, little is known about these perspectives in SOT. This study provides the first assessment of knowledge and perceptions of AI among patients and healthcare professionals in this field. Methods: A cross-sectional study was conducted among SOT patients and HP. Patients were recruited through associations, and HP through the French Society of Transplantation. Data were collected using a web-based questionnaire including open-ended and closed items addressing sociodemographic characteristics, declared knowledge, and perception of AI and its applications in healthcare and SOT. Thematic coding was used for qualitative data, regression models for association analyses, and reliability testing was assessed (Cronbach's α > 0.7). Results: 218 patients and 92 HP participated. Patients reported low AI declared knowledge (mean 2.4/10), while HP suggested slightly higher levels (3.8/10). 140 patients had heard of AI in healthcare, and very few were aware of its use in SOT ( n = 20). Although most HP were familiar with AI in healthcare ( n = 71), declared knowledge of AI applications in SOT remained limited ( n = 39). Overall, both groups expressed positive perceptions of AI in SOT, with concerns mainly related to dehumanization of care and potential errors. Patients largely viewed AI as a complement too, rather than a replacement for healthcare professionals. Discussion: As declared knowledge was associated with perceptions of AI, these findings highlight the importance of targeted educational interventions to promote informed integration of AI in SOT. This exploratory study provides valuable insights into potential facilitators and barriers to adoption, providing actionable insights to guide implementation strategies and policy development in transplant care.
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Digital Health
- Vol. 8, 1834577
Open AccessAssessing knowledge and perception of artificial intelligence in solid organ transplantation
Introduction: Artificial intelligence (AI) is increasingly integrated into healthcare, reshaping clinical decision-making and care pathways. In solid organ transplantation (SOT), where clinical complexity and uncertainty are high, AI holds particular promise. Yet, beyond technical performance, its successful adoption depends on how it is understood and perceived by patients and healthcare professionals (HP). To date, little is known about these perspectives in SOT. This study provides the first assessment of knowledge and perceptions of AI among patients and healthcare professionals in this field. Methods: A cross-sectional study was conducted among SOT patients and HP. Patients were recruited through associations, and HP through the French Society of Transplantation. Data were collected using a web-based questionnaire including open-ended and closed items addressing sociodemographic characteristics, declared knowledge, and perception of AI and its applications in healthcare and SOT. Thematic coding was used for qualitative data, regression models for association analyses, and reliability testing was assessed (Cronbach's α > 0.7). Results: 218 patients and 92 HP participated. Patients reported low AI declared knowledge (mean 2.4/10), while HP suggested slightly higher levels (3.8/10). 140 patients had heard of AI in healthcare, and very few were aware of its use in SOT ( n = 20). Although most HP were familiar with AI in healthcare ( n = 71), declared knowledge of AI applications in SOT remained limited ( n = 39). Overall, both groups expressed positive perceptions of AI in SOT, with concerns mainly related to dehumanization of care and potential errors. Patients largely viewed AI as a complement too, rather than a replacement for healthcare professionals. Discussion: As declared knowledge was associated with perceptions of AI, these findings highlight the importance of targeted educational interventions to promote informed integration of AI in SOT. This exploratory study provides valuable insights into potential facilitators and barriers to adoption, providing actionable insights to guide implementation strategies and policy development in transplant care.
- Open Access
Role of the Pharmacist in Supporting the Use of Connected Health Devices: Example of Connected Watches
The use of Connected Medical Devices (CMDs) is growing significantly throughout the world. Although they are not dispensed in pharmacies and are not part of the pharmacy-only drug dispensing system, clinical pharmacists must be able to support patients in the use of these new technologies, which are central to their care. The aim of this study is to identify the role of the community pharmacist in supporting patients who use CMDs, using the case of connected watches in electrophysiology. Semi-structured interviews were conducted between 15 February and 20 April 2024 by a pharmacy student. The questionnaires were drafted in collaboration with a pharmacist, a cardiac electrophysiologist, a methodologist specializing in the evaluation of medical devices, and an ethical philosopher specializing in the support and acceptability of new technologies. The aim of these questionnaires was to study the use of connected watches and support for patients who own them. A total of 4 cardiac electrophysiologists and 10 cardiac electrophysiology patients were interviewed, and then 6 pharmacists were also questioned about the roles identified by physicians and patients. This study identified a major need on the part of specialist physicians for clinical pharmacist support in helping patients use connected watches. Patients expressed a high level of confidence in their pharmacists to support them, and in the motivation of pharmacists’ ability to take up these challenges. A number of challenges remain, such as the effective integration of this support into pharmacy practice, remuneration, and the organization of collaboration between clinical pharmacists and hospital electrophysiologists.
Open AccessRole of the Pharmacist in Supporting the Use of Connected Health Devices: Example of Connected Watches
The use of Connected Medical Devices (CMDs) is growing significantly throughout the world. Although they are not dispensed in pharmacies and are not part of the pharmacy-only drug dispensing system, clinical pharmacists must be able to support patients in the use of these new technologies, which are central to their care. The aim of this study is to identify the role of the community pharmacist in supporting patients who use CMDs, using the case of connected watches in electrophysiology. Semi-structured interviews were conducted between 15 February and 20 April 2024 by a pharmacy student. The questionnaires were drafted in collaboration with a pharmacist, a cardiac electrophysiologist, a methodologist specializing in the evaluation of medical devices, and an ethical philosopher specializing in the support and acceptability of new technologies. The aim of these questionnaires was to study the use of connected watches and support for patients who own them. A total of 4 cardiac electrophysiologists and 10 cardiac electrophysiology patients were interviewed, and then 6 pharmacists were also questioned about the roles identified by physicians and patients. This study identified a major need on the part of specialist physicians for clinical pharmacist support in helping patients use connected watches. Patients expressed a high level of confidence in their pharmacists to support them, and in the motivation of pharmacists’ ability to take up these challenges. A number of challenges remain, such as the effective integration of this support into pharmacy practice, remuneration, and the organization of collaboration between clinical pharmacists and hospital electrophysiologists.
- Open Access
- 25 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 11 (4) , 387-392
Trial-level surrogacy of non-high-density and low-density lipoprotein cholesterol reduction on the clinical efficacy of statins
LDL cholesterol (LDL - c) and non-HDL cholesterol (non-HDL-c) are prognostic factors of cardiovascular risk. However, their validity as trial-level surrogates for cardiovascular outcomes is debated. This study aimed to determine whether LDL - c and non-HDL-c are reliable surrogates for cardiovascular events in statin trials, and to explore discrepancies in previous studies. We conducted an umbrella review of meta-analyses of randomized controlled trials (RCTs) assessing statin efficacy versus placebo or usual care on all-cause mortality and cardiovascular events. We search studies published between 1987 and August 2023 from PubMed, Embase, and the Cochrane Library. Baseline lipid levels, absolute risk differences (ARDs), and hazard ratios or risk ratios (RRs) for major cardiovascular events and all-cause or cardiovascular mortality were analysed. Weighted linear regressions between log RR or ARD, and absolute difference in non-HDL-c or LDL - c were performed. The coefficients of determination (R2trial) were calculated, with their 95% CI computed through bootstrapping. The surrogate threshold effect (STE) was also estimated. Twenty RCTs and 194 686 participants were included, with a median follow-up of 4.85 years. Statin treatment showed significant efficacy in improving all clinical outcomes. However, the association between treatment effects on LDL - c or non-HDL-c reduction and clinical outcomes was weak. The R²trial were ranging from 0 to 0.1 for LDL - c, and from 0 to 0.04 for non-HDL-c. The STE for major adverse cardiovascular event was 0.76 (0.36–1.69) mmol/L for LDL - c, and 0.87 (0.49–2.19) mmol/L for non-HDL-c. Neither LDL - c nor non-HDL-c demonstrated trial-level surrogacy for predicting treatment effects on mortality and cardiovascular events in statin trials. Although they are relevant biomarkers for the follow-up of patients treated with statins, their reduction does not reliably predict a similar reduction in cardiovascular risk. As such, they should not be used as pivotal evidence in drug trials.
- 25 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 11 (4) , 387-392
Open AccessTrial-level surrogacy of non-high-density and low-density lipoprotein cholesterol reduction on the clinical efficacy of statins
LDL cholesterol (LDL - c) and non-HDL cholesterol (non-HDL-c) are prognostic factors of cardiovascular risk. However, their validity as trial-level surrogates for cardiovascular outcomes is debated. This study aimed to determine whether LDL - c and non-HDL-c are reliable surrogates for cardiovascular events in statin trials, and to explore discrepancies in previous studies. We conducted an umbrella review of meta-analyses of randomized controlled trials (RCTs) assessing statin efficacy versus placebo or usual care on all-cause mortality and cardiovascular events. We search studies published between 1987 and August 2023 from PubMed, Embase, and the Cochrane Library. Baseline lipid levels, absolute risk differences (ARDs), and hazard ratios or risk ratios (RRs) for major cardiovascular events and all-cause or cardiovascular mortality were analysed. Weighted linear regressions between log RR or ARD, and absolute difference in non-HDL-c or LDL - c were performed. The coefficients of determination (R2trial) were calculated, with their 95% CI computed through bootstrapping. The surrogate threshold effect (STE) was also estimated. Twenty RCTs and 194 686 participants were included, with a median follow-up of 4.85 years. Statin treatment showed significant efficacy in improving all clinical outcomes. However, the association between treatment effects on LDL - c or non-HDL-c reduction and clinical outcomes was weak. The R²trial were ranging from 0 to 0.1 for LDL - c, and from 0 to 0.04 for non-HDL-c. The STE for major adverse cardiovascular event was 0.76 (0.36–1.69) mmol/L for LDL - c, and 0.87 (0.49–2.19) mmol/L for non-HDL-c. Neither LDL - c nor non-HDL-c demonstrated trial-level surrogacy for predicting treatment effects on mortality and cardiovascular events in statin trials. Although they are relevant biomarkers for the follow-up of patients treated with statins, their reduction does not reliably predict a similar reduction in cardiovascular risk. As such, they should not be used as pivotal evidence in drug trials.
- Open Access
- 27 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0314430
The reproducibility of protocols used to mediate a current-induced vasodilation in the human cutaneous microcirculation
Introduction: Current-induced vasodilation (CIV) can be used to assess the prostacyclin (PGI2) pathway. This study, for the first time, evaluated the reproducibility of several protocols used to mediate a CIV. Methods: Three CIV protocols were evaluated in 10 healthy participants who completed four testing sessions. Two testing sessions were conducted on the calf, separated by a period of seven days allowing interday reproducibility to be assessed. Two testing sessions were also conducted seven days apart on the forearm. At each testing session, cutaneous microvascular assessments were conducted for one hour on the right limb of interest before assessments were immediately performed on the left limb, allowing for intersite, intraday reproducibility to be evaluated. Assessments were then repeated at the same site on the right limb, allowing for intrasite, intraday reproducibility to be evaluated. Reproducibility was assessed using the within-subject coefficients of variation and the intra-class correlation coefficients. Results: Protocol A (Pulses of 0.03, 0.06, 0.09, 0.12, 0.15, and 0.18 mA for 10 s each; 60 s intervals), Protocol B (0.1 mA for 60 s), and Protocol C (2 pulses of 0.1 mA for 10s each; 240 s interval) had good to excellent interday reproducibility for calf and forearm assessments. The intrasite, intraday reproducibility of each protocol was less clear. Intersite testing didn’t improve intraday reproducibility. Reproducibility was consistently unacceptable when the microvascular response to the electrical stimulation was expressed as the absolute change and the percentage change between baseline values and the maximal plateau. A microvascular response wasn’t induced ∼10% of assessments on either the calf or forearm. Conclusions: This study indicates that a CIV is most reproducible with interday testing and when data are expressed as the maximal plateau in perfusion units or as cutaneous vascular conductance, and as the area under the curve.
- 27 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0314430
Open AccessThe reproducibility of protocols used to mediate a current-induced vasodilation in the human cutaneous microcirculation
Introduction: Current-induced vasodilation (CIV) can be used to assess the prostacyclin (PGI2) pathway. This study, for the first time, evaluated the reproducibility of several protocols used to mediate a CIV. Methods: Three CIV protocols were evaluated in 10 healthy participants who completed four testing sessions. Two testing sessions were conducted on the calf, separated by a period of seven days allowing interday reproducibility to be assessed. Two testing sessions were also conducted seven days apart on the forearm. At each testing session, cutaneous microvascular assessments were conducted for one hour on the right limb of interest before assessments were immediately performed on the left limb, allowing for intersite, intraday reproducibility to be evaluated. Assessments were then repeated at the same site on the right limb, allowing for intrasite, intraday reproducibility to be evaluated. Reproducibility was assessed using the within-subject coefficients of variation and the intra-class correlation coefficients. Results: Protocol A (Pulses of 0.03, 0.06, 0.09, 0.12, 0.15, and 0.18 mA for 10 s each; 60 s intervals), Protocol B (0.1 mA for 60 s), and Protocol C (2 pulses of 0.1 mA for 10s each; 240 s interval) had good to excellent interday reproducibility for calf and forearm assessments. The intrasite, intraday reproducibility of each protocol was less clear. Intersite testing didn’t improve intraday reproducibility. Reproducibility was consistently unacceptable when the microvascular response to the electrical stimulation was expressed as the absolute change and the percentage change between baseline values and the maximal plateau. A microvascular response wasn’t induced ∼10% of assessments on either the calf or forearm. Conclusions: This study indicates that a CIV is most reproducible with interday testing and when data are expressed as the maximal plateau in perfusion units or as cutaneous vascular conductance, and as the area under the curve.
- 10 May 2023
- Published by Elsevier in La Revue de l'Infirmière
- Vol. 72 (291) , 49-50
Partie 2 Interactions « pharmacodynamiques »
- 10 May 2023
- Published by Elsevier in La Revue de l'Infirmière
- Vol. 72 (291) , 49-50
Partie 2 Interactions « pharmacodynamiques »
- 21 March 2023
- Published by Elsevier in La Revue de l'Infirmière
- Vol. 72 (289) , 51-52
Partie 1: les interactions pharmacocinétiques
- 21 March 2023
- Published by Elsevier in La Revue de l'Infirmière
- Vol. 72 (289) , 51-52
Partie 1: les interactions pharmacocinétiques
- 25 July 2022
- Published by Elsevier in Transplant Immunology
- Vol. 74, 101678
Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients
- 25 July 2022
- Published by Elsevier in Transplant Immunology
- Vol. 74, 101678
Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients
- Open Access
Information and Communication Technologies in Lung Transplantation: Perception of Patients and Medical Teams
Optimal therapeutic management is a major determinant of patient prognosis and healthcare costs. Information and communication technologies (ICTs) represent an opportunity to enhance therapeutic management in complex chronic diseases, such as lung transplantation (LT). The objective of this study was to assess the preferences of LT patients and healthcare professionals regarding ICTs in LT therapeutic management. A cross-sectional opinion survey was conducted among lung transplant patients and healthcare professionals from the French lung transplantation centers. Five ICTs were defined (SMS, email, phone, internet, and smartphone application) in addition to face-to-face communication. An unsupervised approach by Principal Component Analysis (PCA) identified lung transplant patient profiles according to their preferences for ICTs. Fifty-three lung transplant patients and 15 healthcare professionals of the French LT centers were included. Both expected ICTs for treatment management and communication. Phone call, face-to-face, and emails were the most preferred communication tools for treatment changes and initiation. PCA identified four ICTs-related profiles (“no ICT”, “email”, “SMS”, and “oral communication”). “Email” and “oral communication” profiles are mainly concerned with treatment changes and transmission of new prescriptions. The “SMS” profile expected reminders for healthcare appointments and optimizing therapeutic management. This study provides practical guidance to enhance LT therapeutic management by ICT intervention. The type of ICT used should take into account patient profiles to improve adherence and thereby the prognosis. A combination of strategies including information, education by a multidisciplinary team, and reminders is a promising approach to ensure an optimal management of our patients.
Open AccessInformation and Communication Technologies in Lung Transplantation: Perception of Patients and Medical Teams
Optimal therapeutic management is a major determinant of patient prognosis and healthcare costs. Information and communication technologies (ICTs) represent an opportunity to enhance therapeutic management in complex chronic diseases, such as lung transplantation (LT). The objective of this study was to assess the preferences of LT patients and healthcare professionals regarding ICTs in LT therapeutic management. A cross-sectional opinion survey was conducted among lung transplant patients and healthcare professionals from the French lung transplantation centers. Five ICTs were defined (SMS, email, phone, internet, and smartphone application) in addition to face-to-face communication. An unsupervised approach by Principal Component Analysis (PCA) identified lung transplant patient profiles according to their preferences for ICTs. Fifty-three lung transplant patients and 15 healthcare professionals of the French LT centers were included. Both expected ICTs for treatment management and communication. Phone call, face-to-face, and emails were the most preferred communication tools for treatment changes and initiation. PCA identified four ICTs-related profiles (“no ICT”, “email”, “SMS”, and “oral communication”). “Email” and “oral communication” profiles are mainly concerned with treatment changes and transmission of new prescriptions. The “SMS” profile expected reminders for healthcare appointments and optimizing therapeutic management. This study provides practical guidance to enhance LT therapeutic management by ICT intervention. The type of ICT used should take into account patient profiles to improve adherence and thereby the prognosis. A combination of strategies including information, education by a multidisciplinary team, and reminders is a promising approach to ensure an optimal management of our patients.